ZNF500 abolishes breast cancer proliferation and sensitizes chemotherapy by stabilizing P53 via competing with MDM2

Xiaowen Ma,Mingwei Fan,Kaibo Yang,Yuanyuan Wang,Ran Hu,Mengyao Guan,Yuekang Hou,Jiao Ying,Ning Deng,Qingchang Li,Guiyang Jiang,Yong Zhang,Xiupeng Zhang
DOI: https://doi.org/10.1111/cas.15947
IF: 5.7
2023-09-14
Cancer Science
Abstract:ZNF500 is elevated in breast cancer, whose expression significantly negatively correlated with advanced TNM stage, positive lymph node metastasis and poor prognosis. ZNF500 binds to the C‐terminal domain of P53 directly via its C2H2 domain, which may block the interaction between MDM2 and P53, thus stabilizing P53. Overexpression of ZNF500 accelerated DNA damage and sensitized chemotherapy treatment, which was confirmed in human breast cancer with neoadjuvant chemotherapy. Zinc finger protein 500 (ZNF500) has an unknown expression pattern and biological function in human tissues. Our study revealed that the ZNF500 mRNA and protein levels were higher in breast cancer tissues than those in their normal counterparts. However, ZNF500 expression was negatively correlated with advanced TNM stage (p = 0.018), positive lymph node metastasis (p = 0.014), and a poor prognosis (p
oncology
What problem does this paper attempt to address?